Market Cap 39.18M
Revenue (ttm) 25.18M
Net Income (ttm) -11.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -47.22%
Debt to Equity Ratio 0.00
Volume 48,600
Avg Vol 52,588
Day's Range N/A - N/A
Shares Out 8.00M
Stochastic %K 49%
Beta 0.34
Analysts Strong Sell
Price Target $21.35

Company Profile

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also deve...

Industry: Medical Devices
Sector: Healthcare
Phone: 973 290 0097
Fax: 973 290 9171
Address:
200 Forge Way, Suite 205, Rockaway, United States
juice_rock
juice_rock Oct. 24 at 3:39 PM
$ECOR classic pump n' dump
0 · Reply
taxplanr
taxplanr Oct. 24 at 2:31 PM
Using the bodies own mitochondria to combat cancers chronic illnesses and autoimmune diseases is what emf device companies like $ECOR can do Not failed malignantRNA platforms with toxic chemo does $BNTX $MRNA $BMY
0 · Reply
taxplanr
taxplanr Oct. 24 at 2:27 PM
0 · Reply
taxplanr
taxplanr Oct. 23 at 10:48 AM
EMF and red light therapy being used for treating cancers chronic pain and autoimmune diseases $ECOR https://rumble.com/v70nlls-jonathan-otto-joins-silk-to-discuss-red-light-and-pemf-therapy.html?mref=1v6ax&mc=85ofo
0 · Reply
taxplanr
taxplanr Oct. 17 at 11:33 AM
$ECOR emf can be used in combination with diet and other therapies to cure cancer Wait for it
0 · Reply
Moneymastermind99
Moneymastermind99 Oct. 16 at 2:36 PM
🚀 $TGL — Quiet Before the Next Wave? TGL just dropped its 10-K, showing solid progress: revenue up YoY, net losses narrowing, and platform expansion underway. The clean filing clears the path for new catalysts — especially that rumored $100M crypto treasury update and possible F&B flagship expansion tied to its ZCITY platform. Market cap nearly doubled this week despite a price dip — a sign smart money may be positioning early. Eyes on the next 8-K or treasury news drop 👀 Low float + real platform growth + fresh capital strategy = setup for a major squeeze. Similar low-float runners catching volume today: $ECOR , $GWAV , $ITP . 🎯 Short-term PT: $1.20-$1.60 ⚡ Speculative breakout range: $2+ if crypto treasury confirmed. #TGL #Crypto #Fintech #SmallCaps #Momentum
0 · Reply
EvilUrges
EvilUrges Oct. 16 at 8:37 AM
$ECOR getting Facebook ads for Truvaga. What I found interesting is a guy named Ben Greenfield was promoting it. I used to follow Ben a long time ago back in his Ironman training days when I was running marathons. Learned a lot from him. About Ben: Ben Greenfield is a biohacker, nutritionist, physiologist, fitness coach, competitive athlete and New York Times bestselling author of 13 books, including the wildly popular titles Beyond Training and Boundless. In the Boundless Cookbook he takes over 20 years of experience in the health industry - along with family recipes inspired by his wife and kids - to produce a creative, unique and mouth-watering collection of never-before-seen recipes.
0 · Reply
cgcapitalresearch
cgcapitalresearch Oct. 9 at 6:29 PM
$ECOR Earnings Preview - Scaling Bioelectronic Medicine and Wellness Platforms - We forecast FY26 revenue of $40.5M (+35% YoY), narrowing the GAAP net loss to $(4.1M) and achieving positive EBITDA in 4Q26. At a current EV of just $29M, ECOR trades at ~1× EV/2025E revenue, well below peer averages of 3.5–4.0× for high-growth neuro-device companies. We reiterate our Buy rating and $25 base-case price target, with a $35 bull-case scenario reflecting 5× FY26E revenue.[Read More: https://hubs.ly/Q03M-kPx0]
0 · Reply
taxplanr
taxplanr Oct. 6 at 3:05 PM
$ECOR lender converted $2.5 million of debt into equity at a price of $8.62
1 · Reply
TraderJay85
TraderJay85 Oct. 5 at 10:13 PM
This week watch list with support/stop. $EEIQ .4577 stop $NYC 9.40 stop $NIVF 1.76 stop $ECOR 4.90 stop $LVLU 4.90 stop Never hold under support. if it goes below then sell. Jump back in if it comes back to last support. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
0 · Reply
Latest News on ECOR
electroCore Appoints Elena Bonfiglioli to Board of Directors

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

electroCore Appoints Elena Bonfiglioli to Board of Directors


electroCore, Inc. (ECOR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:18 PM EDT - 2 months ago

electroCore, Inc. (ECOR) Q2 2025 Earnings Call Transcript


electroCore Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 2 months ago

electroCore Announces Second Quarter 2025 Financial Results


electroCore to Participate in Upcoming Investor Conferences

Jul 22, 2025, 4:05 PM EDT - 3 months ago

electroCore to Participate in Upcoming Investor Conferences


electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:16 PM EDT - 6 months ago

electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript


electroCore Announces First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 6 months ago

electroCore Announces First Quarter 2025 Financial Results


electroCore's Truvaga™ Now Works with the Apple Health app

May 1, 2025, 8:00 AM EDT - 6 months ago

electroCore's Truvaga™ Now Works with the Apple Health app


electroCore to Participate at the Planet MicroCap Showcase

Apr 16, 2025, 8:00 AM EDT - 6 months ago

electroCore to Participate at the Planet MicroCap Showcase


electroCore Extends VA Contract for Five Years

Mar 31, 2025, 8:00 AM EDT - 7 months ago

electroCore Extends VA Contract for Five Years


electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 9:36 PM EDT - 8 months ago

electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript


electroCore Announces Full Year 2024 Financial Results

Mar 12, 2025, 4:05 PM EDT - 8 months ago

electroCore Announces Full Year 2024 Financial Results


electroCore to Participate at Upcoming Investor Conferences

Mar 5, 2025, 8:00 AM EST - 8 months ago

electroCore to Participate at Upcoming Investor Conferences


electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:18 PM EST - 1 year ago

electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript


electroCore Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:01 PM EST - 1 year ago

electroCore Announces Third Quarter 2024 Financial Results


electroCore to Participate at LD Micro Main Event VXII

Oct 14, 2024, 8:00 AM EDT - 1 year ago

electroCore to Participate at LD Micro Main Event VXII


electroCore, Inc. (ECOR) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 4:27 AM EDT - 1 year ago

electroCore, Inc. (ECOR) Q2 2024 Earnings Call Transcript


electroCore Announces Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

electroCore Announces Second Quarter 2024 Financial Results


electroCore Announces the Commercial Launch of TAC-STIM™

Jun 25, 2024, 8:00 AM EDT - 1 year ago

electroCore Announces the Commercial Launch of TAC-STIM™


electroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript

May 8, 2024, 10:19 PM EDT - 1 year ago

electroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript


electroCore Announces First Quarter 2024 Financial Results

May 8, 2024, 4:05 PM EDT - 1 year ago

electroCore Announces First Quarter 2024 Financial Results


juice_rock
juice_rock Oct. 24 at 3:39 PM
$ECOR classic pump n' dump
0 · Reply
taxplanr
taxplanr Oct. 24 at 2:31 PM
Using the bodies own mitochondria to combat cancers chronic illnesses and autoimmune diseases is what emf device companies like $ECOR can do Not failed malignantRNA platforms with toxic chemo does $BNTX $MRNA $BMY
0 · Reply
taxplanr
taxplanr Oct. 24 at 2:27 PM
0 · Reply
taxplanr
taxplanr Oct. 23 at 10:48 AM
EMF and red light therapy being used for treating cancers chronic pain and autoimmune diseases $ECOR https://rumble.com/v70nlls-jonathan-otto-joins-silk-to-discuss-red-light-and-pemf-therapy.html?mref=1v6ax&mc=85ofo
0 · Reply
taxplanr
taxplanr Oct. 17 at 11:33 AM
$ECOR emf can be used in combination with diet and other therapies to cure cancer Wait for it
0 · Reply
Moneymastermind99
Moneymastermind99 Oct. 16 at 2:36 PM
🚀 $TGL — Quiet Before the Next Wave? TGL just dropped its 10-K, showing solid progress: revenue up YoY, net losses narrowing, and platform expansion underway. The clean filing clears the path for new catalysts — especially that rumored $100M crypto treasury update and possible F&B flagship expansion tied to its ZCITY platform. Market cap nearly doubled this week despite a price dip — a sign smart money may be positioning early. Eyes on the next 8-K or treasury news drop 👀 Low float + real platform growth + fresh capital strategy = setup for a major squeeze. Similar low-float runners catching volume today: $ECOR , $GWAV , $ITP . 🎯 Short-term PT: $1.20-$1.60 ⚡ Speculative breakout range: $2+ if crypto treasury confirmed. #TGL #Crypto #Fintech #SmallCaps #Momentum
0 · Reply
EvilUrges
EvilUrges Oct. 16 at 8:37 AM
$ECOR getting Facebook ads for Truvaga. What I found interesting is a guy named Ben Greenfield was promoting it. I used to follow Ben a long time ago back in his Ironman training days when I was running marathons. Learned a lot from him. About Ben: Ben Greenfield is a biohacker, nutritionist, physiologist, fitness coach, competitive athlete and New York Times bestselling author of 13 books, including the wildly popular titles Beyond Training and Boundless. In the Boundless Cookbook he takes over 20 years of experience in the health industry - along with family recipes inspired by his wife and kids - to produce a creative, unique and mouth-watering collection of never-before-seen recipes.
0 · Reply
cgcapitalresearch
cgcapitalresearch Oct. 9 at 6:29 PM
$ECOR Earnings Preview - Scaling Bioelectronic Medicine and Wellness Platforms - We forecast FY26 revenue of $40.5M (+35% YoY), narrowing the GAAP net loss to $(4.1M) and achieving positive EBITDA in 4Q26. At a current EV of just $29M, ECOR trades at ~1× EV/2025E revenue, well below peer averages of 3.5–4.0× for high-growth neuro-device companies. We reiterate our Buy rating and $25 base-case price target, with a $35 bull-case scenario reflecting 5× FY26E revenue.[Read More: https://hubs.ly/Q03M-kPx0]
0 · Reply
taxplanr
taxplanr Oct. 6 at 3:05 PM
$ECOR lender converted $2.5 million of debt into equity at a price of $8.62
1 · Reply
TraderJay85
TraderJay85 Oct. 5 at 10:13 PM
This week watch list with support/stop. $EEIQ .4577 stop $NYC 9.40 stop $NIVF 1.76 stop $ECOR 4.90 stop $LVLU 4.90 stop Never hold under support. if it goes below then sell. Jump back in if it comes back to last support. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 3 at 10:26 PM
0 · Reply
TraderJay85
TraderJay85 Oct. 1 at 10:04 PM
Watch list with support/stop. i have 38 of these but narrowed them down to 20. Ill attach pic of the whole list though. $AEHL 3.40 stop. $ECOR 4.70 stop $IPDN 3.75 stop. $LVLU 4.65 stop $NYC 9.40 stop. Do not hold under support. You can jump back in if it goes back over support. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER.
0 · Reply
Trekingirl
Trekingirl Oct. 1 at 12:26 PM
0 · Reply
taxplanr
taxplanr Sep. 29 at 2:38 PM
$ECOR https://investor.electrocore.com/news-releases/news-release-details/electrocore-announces-reimbursement-approval-gammacoretm
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 29 at 12:14 PM
$ECOR electroCore Announces Its GammaCore Sapphire Non-Invasive Vagus Nerve Stimulation Device Has Been Included In Long-Term Reimbursement Policy By Belgium's National Institute For Health And Disability Insurance
0 · Reply
taxplanr
taxplanr Sep. 26 at 2:02 PM
$ABBV these parkinsons drugs are always nightmares Just about every auto-immune disease can be much better treated with a Truvaga Plus from $ECOR which can relax the whole nervous system without any side effects
0 · Reply
taxplanr
taxplanr Sep. 22 at 1:48 PM
$ECOR Truvaga Plus named Best Relaxation Device 2025 https://investor.electrocore.com/news-releases/news-release-details/electrocores-truvagatm-plus-named-best-relaxation-gadget
0 · Reply
RickAllen817
RickAllen817 Sep. 21 at 10:19 AM
$ECOR Medical device innovation. Pre-revenue speculation. High risk/reward setup. No pattern.
0 · Reply
Trekingirl
Trekingirl Sep. 19 at 8:42 PM
$ECOR Insiders have been buying over the last year but..... "WHO THE FUCK IS HOLDING THE PRICE BACK ON THIS LOW FLOAT, LOW VOLUME STOCK?" Doesn't see much action now, but when it rips, it'll most likely be HUGE.
0 · Reply
DisMania
DisMania Sep. 15 at 11:53 AM
$ECOR Yikes, this was nearly $20 earlier this year and it's been a falling knife since. 25 cent stock in the making
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 11 at 8:52 AM
$ECOR Outstanding article that hits the mark on ECOR's current state. So if you want to refresh your ECOR insights or learn about ECOR from scratch, this is a must read. https://beyondspx.com/quote/ECOR/analysis/electrocore-s-bioelectronic-power-play-diversification-and-growth-in-chronic-pain-and-wellness-nasdaq-ecor
0 · Reply
taxplanr
taxplanr Sep. 10 at 9:59 PM
$ECOR new controller https://investor.electrocore.com/news-releases/news-release-details/electrocore-announces-inducement-grant-under-nasdaq-listing-2
0 · Reply